Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

X4 Pharmaceuticals (XFOR) Return on Capital Employed (2018 - 2025)

X4 Pharmaceuticals filings provide 8 years of Return on Capital Employed readings, the most recent being 43.17% for Q4 2025.

  • On a quarterly basis, Return on Capital Employed fell 1505.0% to 43.17% in Q4 2025 year-over-year; TTM through Dec 2025 was 43.17%, a 1505.0% decrease, with the full-year FY2025 number at 45.09%, down 1315.0% from a year prior.
  • Return on Capital Employed hit 43.17% in Q4 2025 for X4 Pharmaceuticals, up from 89.21% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 7.61% in Q1 2025 to a low of 132.92% in Q3 2022.
  • Median Return on Capital Employed over the past 5 years was 78.16% (2022), compared with a mean of 70.72%.
  • The widest YoY moves for Return on Capital Employed: up 10117bps in 2025, down -9779bps in 2025.
  • X4 Pharmaceuticals' Return on Capital Employed stood at 81.19% in 2021, then grew by 4bps to 78.07% in 2022, then dropped by 0bps to 78.25% in 2023, then soared by 64bps to 28.12% in 2024, then crashed by -54bps to 43.17% in 2025.
  • The last three reported values for Return on Capital Employed were 43.17% (Q4 2025), 89.21% (Q3 2025), and 111.82% (Q2 2025) per Business Quant data.